CytomX Therapeutics, Inc. (CTMX)
2.58
+0.02
(+0.78%)
USD |
NASDAQ |
Oct 07, 10:25
CytomX Therapeutics Net Income (Quarterly) : -20.67M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.67M |
| March 31, 2026 | -18.25M |
| December 31, 2025 | -26.51M |
| September 30, 2025 | -14.23M |
| June 30, 2025 | -0.154M |
| March 31, 2025 | 23.52M |
| December 31, 2024 | 18.88M |
| September 30, 2024 | 5.736M |
| June 30, 2024 | -6.534M |
| March 31, 2024 | 13.79M |
| December 31, 2023 | 0.837M |
| September 30, 2023 | 2.992M |
| June 30, 2023 | -1.087M |
| March 31, 2023 | -3.311M |
| December 31, 2022 | -8.776M |
| September 30, 2022 | -29.06M |
| June 30, 2022 | -24.18M |
| March 31, 2022 | -31.98M |
| December 31, 2021 | -26.23M |
| September 30, 2021 | -22.58M |
| June 30, 2021 | -19.24M |
| March 31, 2021 | -15.55M |
| December 31, 2020 | -14.70M |
| Date | Value |
|---|---|
| September 30, 2020 | -14.71M |
| June 30, 2020 | -15.68M |
| March 31, 2020 | 12.20M |
| December 31, 2019 | -35.46M |
| September 30, 2019 | -23.70M |
| June 30, 2019 | -28.96M |
| March 31, 2019 | -14.12M |
| December 31, 2018 | -32.23M |
| September 30, 2018 | -23.43M |
| June 30, 2018 | -13.45M |
| March 31, 2018 | -15.49M |
| December 31, 2017 | 0.621M |
| September 30, 2017 | -10.25M |
| June 30, 2017 | -25.22M |
| March 31, 2017 | -8.257M |
| December 31, 2016 | -14.03M |
| September 30, 2016 | -14.66M |
| June 30, 2016 | -14.18M |
| March 31, 2016 | -16.03M |
| December 31, 2015 | -11.49M |
| September 30, 2015 | -11.87M |
| June 30, 2015 | -5.806M |
| March 31, 2015 | -6.211M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.418M |
| Total Expenses (Quarterly) | 22.08M |
| EPS Diluted (Quarterly) | -0.0944 |
| Enterprise Value | 232.33M |
| Gross Profit Margin (Quarterly) | 96.69% |
| Profit Margin (Quarterly) | -1.46K% |
| Earnings Yield | -17.71% |
| Normalized Earnings Yield | -17.73 |